Our data show a significant relationship between secreted levels of vimentin, 8-OHdG, and endostatin with decreased EF and increased diastolic diameter in CD patients and offer new blood biomarkers to predict the risk of cardiomyopathy, HF, and adverse outcomes in CD patients. Here, VIM is linked to cardiomyopathy.